| scholarly article | Q13442814 |
| P50 | author | Mohsen Khademi | Q41423136 |
| Tommy Olsson | Q43130969 | ||
| P2093 | author name string | E Iacobaeus | |
| L Brundin | |||
| C Ryschkewitsch | |||
| E Wallstrom | |||
| Eo Major | |||
| M Gravell | |||
| P2860 | cites work | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | Q22252938 |
| Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy | Q24683776 | ||
| Progressive multifocal leukoencephalopathy in a patient treated with natalizumab | Q28255536 | ||
| Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis | Q28255548 | ||
| Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician | Q28265412 | ||
| Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease | Q31117183 | ||
| Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. | Q33594696 | ||
| Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus | Q33964857 | ||
| Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy | Q34201921 | ||
| Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease | Q34538727 | ||
| Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy | Q34993076 | ||
| JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. | Q35870644 | ||
| Human demyelinating disease and the polyomavirus JCV. | Q36455705 | ||
| Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy | Q36519031 | ||
| Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy | Q36541911 | ||
| The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases | Q37055704 | ||
| Detection of JC virus in cerebrospinal fluid (CSF) samples from patients with progressive multifocal leukoencephalopathy but not in CSF samples from patients with herpes simplex encephalitis, enteroviral meningitis, or multiple sclerosis | Q39553131 | ||
| Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy | Q43474104 | ||
| Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients | Q44118598 | ||
| Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid | Q44305650 | ||
| JC virus remains latent in peripheral blood B lymphocytes but replicates actively in urine from AIDS patients | Q44925922 | ||
| JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. | Q45403289 | ||
| JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls | Q45404806 | ||
| Failure to detect JC virus DNA in cerebrospinal fluid of multiple sclerosis patients | Q45410383 | ||
| A comparative study of BK and JC virus infections in organ transplant recipients | Q45424471 | ||
| Quantification of JC virus DNA in the cerebrospinal fluid of patients with human immunodeficiency virus-associated progressive multifocal leukoencephalopathy--a longitudinal study | Q45746860 | ||
| JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy | Q45751488 | ||
| Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients | Q45755978 | ||
| Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy | Q45879363 | ||
| Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. | Q47763052 | ||
| Progressive multifocal leucoencephalopathy: Detection of papovavirus jc in kidney tissue | Q70154252 | ||
| Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals | Q73305677 | ||
| Seroepidemiology of the human polyomaviruses | Q73445171 | ||
| P433 | issue | 1 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| cerebrospinal fluid | Q54196 | ||
| nucleic acid sequence analysis | Q62088658 | ||
| P304 | page(s) | 28-35 | |
| P577 | publication date | 2008-09-19 | |
| P1433 | published in | Multiple Sclerosis Journal | Q1952449 |
| P1476 | title | Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. | |
| P478 | volume | 15 |
| Q42217179 | An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy |
| Q44396880 | Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents |
| Q45371233 | CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus |
| Q39808939 | Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. |
| Q34324861 | Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy |
| Q37573005 | Chronic viral infections of the central nervous system: Aspects specific to multiple sclerosis |
| Q40039520 | Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies |
| Q83540853 | Drug-induced PML: a global agenda for a global challenge |
| Q82821753 | Fab-arm exchange |
| Q34818048 | Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab |
| Q38186205 | Infections and multiple sclerosis |
| Q34718044 | Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. |
| Q40643909 | Isolation of a monoclonal antibody that recognizes the origin binding domain of JCV, but not SV40, large T-antigen. |
| Q35586120 | JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis |
| Q82412149 | JCV detection in multiple sclerosis patients treated with natalizumab |
| Q42268307 | May New Biomarkers Help us to Predict Progressive Multifocal Leukoencephalopathy in HIV Positive People? |
| Q37778944 | Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? |
| Q38221343 | Natalizumab: risk stratification of individual patients with multiple sclerosis |
| Q30613846 | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section |
| Q37475542 | Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod |
| Q61809978 | Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis? |
| Q33763351 | Progressive multifocal leukoencephalopathy and other forms of JC virus disease |
| Q83630544 | [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy] |
Search more.